What Is Lumvoa, and Why Does It Matter?
Lumvoa (veligrotug-vvze) is an intravenous (IV) medicine used to treat thyroid eye disease (TED). TED is a rare autoimmune condition in which your immune system attacks tissues around the eyes, causing swelling and changes behind the eyes. This can lead to eye bulging (proptosis), double vision (diplopia), pain, and vision changes that affect daily life.
Lumvoa targets the insulin-like growth factor-1 receptor. By attaching to this receptor, it blocks the signals that drive disease activity, although the exact way this helps in TED is not fully known. It is approved for TED irrespective of disease activity or how long you have had it, meaning it can be used for both active (early) and chronic (long-standing) TED.
This approval stands out for two reasons. First, it is the only treatment for TED with FDA labeling that includes data for both active and chronic disease. Second, it is the first product for TED to show a statistically significant benefit for both improvement in double vision and complete clearing of double vision in active and chronic disease. The availability of another treatment option could make a meaningful difference for the many people looking for effective options to manage TED.
Why Was It Approved?
In studies, people who received Lumvoa had greater reductions in eye bulging than those who received a placebo. By week 15, more people on Lumvoa met the response goal for eye bulging. In both active and chronic TED, average eye bulging also fell more with Lumvoa than with a placebo. Improvements began as early as week 3 and continued through week 15.
Double vision improved as well. By week 15, a higher proportion of people on Lumvoa than on placebo had a meaningful drop in diplopia scores. More people also did not have double vision at all in both active and chronic TED.
Safety findings from the studies are important to consider. Infusion reactions occurred in about 9% of people and were usually manageable. Increased blood sugar levels occurred in about 12% of people, and about half of them already had diabetes or trouble with blood sugar control. The label for Lumvoa warns that it may cause severe hearing problems, including hearing loss, and in some cases, these changes may not go away. The label also warns that inflammatory bowel disease (IBD) can get worse. If IBD is suspected, your health care provider should stop treatment and evaluate you.
The most common side effects include muscle cramps, headache, hearing problems, high blood sugar levels, tiredness, diarrhea, ear discomfort, reactions during the infusion, nausea, cold-like symptoms (such as a sore throat or stuffy nose), higher levels of a muscle enzyme called creatine phosphokinase in the blood, dry skin, and high blood pressure.
What Do I Need to Know?
You receive Lumvoa as an IV infusion from your health care provider. The usual plan is one infusion every three weeks for a total of five infusions.
Changes in hearing can occur and may be permanent. Report ringing in the ears, a feeling of fullness, or hearing loss without delay. Watch for gut symptoms that may suggest IBD, such as urgent diarrhea or rectal bleeding with cramping, and seek care promptly. Blood sugar levels can rise during treatment. If you have diabetes, your health care provider may adjust your treatment plan. Your health care provider will check blood sugar levels before and during treatment.
Do not use Lumvoa if you are pregnant. It may harm a fetus. Use effective birth control before treatment, during therapy, and for six months after the last dose. Tell your health care provider right away if you become pregnant during treatment.
The company plans an immediate launch, with prescribing to begin right away.